A UCLA-led research team has discovered a molecular switch that determines whether tiny blood vessels in premature infants’ lungs can regenerate after injury.
Across medicine, environmental studies, public policy, the social sciences and beyond, UCLA scholars in 2025 continued turning discovery into real-world impact.
The study is the first large-scale clinical trial to show that a new oral endocrine therapy outperforms the long-standing standard therapies used for early-stage HR-positive/HER2-negative breast cancer.